JOP20230246A1 - أجسام مضادة لـ cd122 واستخداماتها - Google Patents
أجسام مضادة لـ cd122 واستخداماتهاInfo
- Publication number
- JOP20230246A1 JOP20230246A1 JOJO/P/2023/0246A JOP20230246A JOP20230246A1 JO P20230246 A1 JOP20230246 A1 JO P20230246A1 JO P20230246 A JOP20230246 A JO P20230246A JO P20230246 A1 JOP20230246 A1 JO P20230246A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibody molecules
- antibodies
- molecules
- antigen
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174772P | 2021-04-14 | 2021-04-14 | |
| US202163279762P | 2021-11-16 | 2021-11-16 | |
| PCT/US2022/024620 WO2022221409A1 (en) | 2021-04-14 | 2022-04-13 | Anti-cd122 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230246A1 true JOP20230246A1 (ar) | 2023-10-11 |
Family
ID=81579792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0246A JOP20230246A1 (ar) | 2021-04-14 | 2023-10-11 | أجسام مضادة لـ cd122 واستخداماتها |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20230357420A1 (https=) |
| EP (1) | EP4323402A1 (https=) |
| JP (1) | JP2024513921A (https=) |
| KR (1) | KR20230170672A (https=) |
| AU (1) | AU2022256455A1 (https=) |
| BR (1) | BR112023021297A2 (https=) |
| CA (1) | CA3215058A1 (https=) |
| CL (2) | CL2023003048A1 (https=) |
| CO (1) | CO2023015254A2 (https=) |
| CR (1) | CR20230523A (https=) |
| DO (1) | DOP2023000211A (https=) |
| EC (1) | ECSP23085780A (https=) |
| GE (3) | GEAP202316382A (https=) |
| IL (1) | IL307267A (https=) |
| JO (1) | JOP20230246A1 (https=) |
| MX (1) | MX2023012218A (https=) |
| PE (1) | PE20240086A1 (https=) |
| PH (1) | PH12023552784A1 (https=) |
| WO (1) | WO2022221409A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025537224A (ja) * | 2022-11-07 | 2025-11-14 | アナプティスバイオ インコーポレイティッド | Ｃｄ１２２結合剤およびその使用方法 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
-
2022
- 2022-04-13 PH PH1/2023/552784A patent/PH12023552784A1/en unknown
- 2022-04-13 GE GEAP202316382A patent/GEAP202316382A/en unknown
- 2022-04-13 CR CR20230523A patent/CR20230523A/es unknown
- 2022-04-13 GE GEAP202416574A patent/GEAP202416574A/en unknown
- 2022-04-13 JP JP2023561755A patent/JP2024513921A/ja active Pending
- 2022-04-13 WO PCT/US2022/024620 patent/WO2022221409A1/en not_active Ceased
- 2022-04-13 MX MX2023012218A patent/MX2023012218A/es unknown
- 2022-04-13 BR BR112023021297A patent/BR112023021297A2/pt unknown
- 2022-04-13 IL IL307267A patent/IL307267A/en unknown
- 2022-04-13 CA CA3215058A patent/CA3215058A1/en active Pending
- 2022-04-13 KR KR1020237034415A patent/KR20230170672A/ko active Pending
- 2022-04-13 PE PE2023002851A patent/PE20240086A1/es unknown
- 2022-04-13 AU AU2022256455A patent/AU2022256455A1/en active Pending
- 2022-04-13 GE GEAP202216382A patent/GEP20257805B/en unknown
- 2022-04-13 EP EP22720859.2A patent/EP4323402A1/en active Pending
-
2023
- 2023-06-16 US US18/336,478 patent/US20230357420A1/en not_active Abandoned
- 2023-06-16 US US18/336,404 patent/US20230322944A1/en active Pending
- 2023-09-29 DO DO2023000211A patent/DOP2023000211A/es unknown
- 2023-10-11 JO JOJO/P/2023/0246A patent/JOP20230246A1/ar unknown
- 2023-10-12 CL CL2023003048A patent/CL2023003048A1/es unknown
- 2023-11-10 CO CONC2023/0015254A patent/CO2023015254A2/es unknown
- 2023-11-13 EC ECSENADI202385780A patent/ECSP23085780A/es unknown
-
2024
- 2024-09-24 CL CL2024002847A patent/CL2024002847A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20257805B (en) | 2025-10-10 |
| AU2022256455A1 (en) | 2023-10-12 |
| CL2023003048A1 (es) | 2024-04-12 |
| KR20230170672A (ko) | 2023-12-19 |
| AU2022256455A9 (en) | 2023-10-26 |
| WO2022221409A1 (en) | 2022-10-20 |
| DOP2023000211A (es) | 2024-01-15 |
| CR20230523A (es) | 2024-01-23 |
| GEAP202316382A (en) | 2023-12-25 |
| CA3215058A1 (en) | 2022-10-20 |
| PE20240086A1 (es) | 2024-01-16 |
| US20230357420A1 (en) | 2023-11-09 |
| CL2024002847A1 (es) | 2025-01-10 |
| CO2023015254A2 (es) | 2023-11-20 |
| JP2024513921A (ja) | 2024-03-27 |
| BR112023021297A2 (pt) | 2023-12-12 |
| EP4323402A1 (en) | 2024-02-21 |
| US20230322944A1 (en) | 2023-10-12 |
| GEAP202416574A (en) | 2024-09-10 |
| MX2023012218A (es) | 2023-12-15 |
| PH12023552784A1 (en) | 2024-04-15 |
| ECSP23085780A (es) | 2024-01-31 |
| IL307267A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230246A1 (ar) | أجسام مضادة لـ cd122 واستخداماتها | |
| EA202090364A1 (ru) | Антитела с функциональными доменами в области изгиба между вариабельным и константным доменами | |
| JOP20200078B1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| UA117575C2 (uk) | Антитіло, яке специфічно зв'язується з il-17a та його застосування | |
| CY1117036T1 (el) | Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων | |
| CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
| BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
| BRPI0610796B8 (pt) | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo | |
| CL2012002081A1 (es) | Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria. | |
| EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
| ECSP23053070A (es) | Anticuerpos multiespecíficos con especificidad para il-4r e il-31 | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
| MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
| ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
| BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| BR112021017860A2 (pt) | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica | |
| CN111918878A (zh) | 抗gitr抗体及其用途 | |
| MX2024006969A (es) | Anticuerpos dlk1 y metodos de tratamiento del cancer. | |
| EA202091596A1 (ru) | Антитела к pd-1 и способы лечения |